Aktuelle saker
Jeg vil se flere saker
14. mars 2024
Revmatologen nr.1 2024
23. februar 2024
Med sans for sjeldne sykdommer
9. februar 2024
Metodeboken: Eksempler på ultralydveiledede injeksjoner (video)
6. februar 2024
NRF medlemsmiddag under EULAR 2024
6. februar 2024
CHANGE Study 2024
23. januar 2024
Ultralydkurs for spesialister 15.-17.april 2024
5. januar 2024
EULAR 2024
16. oktober 2023
Fra Dagens Medisin - Podcast om Revmatologi
Finn informasjon om
Kommende kurs og møter
Forskningsmidler/stipend
Norske kvalitetsregistre
Regelverk, koding, prioritering
Nasjonale kompetansetjenester
Nyttige lenker
Finn informasjon om
Kommende kurs og møter
Forskningsmidler/stipend
Norske kvalitetsregistre
Regelverk, koding, prioritering
Nasjonale kompetansetjenester
Nyttige lenker
Scandinavian Journal of Rheumatology Aims & Scope
26. januar 2024
Volume 53, Issue 3, May 2024, Page 188-198.
20. juni 2023
Volume 53, Issue 3, May 2024, Page 180-187.
5. februar 2024
Volume 53, Issue 3, May 2024, Page 173-179.
Scandinavian Journal of Rheumatology
Annals of the Rheumatic Diseases
15. mai 2024
We read with interest and surprise the study of Zhao et al. on the therapeutic effects of the SGLT2 inhibitor empagliflozin in systemic lupus erythematosus (SLE) and lupus-like nephritis of MRLlpr mice.1 The concerns are the following: (1) SGLT2 is a sodium-glucose transporter mainly expressed in the proximal tubule of the kidney. SGLT2 inhibitors enhance sodium and glucose excretion into the urine, and also other mechanisms that exert beneficial effects on the cardiorenal system, glucose metabolism and haematopoiesis. In contrast, no direct effects on autoimmunity are to be expected. The fact that the authors report a suppression of all aspects of SLE and the related autoimmunity, that is, the profound suppression of total IgG and of double stranded DNA (dsDNA) autoantibodies produced by autoreactive immune cell clones in lymphoid organs and bone marrow, raises serious doubts, and no mechanism for this immunosuppressive effect is provided. (2) The...
15. mai 2024
We would like to thank Soler, Jacobs-Cachá and Anders1 for their interest in our work on sodium glucose cotransporter (SGLT) 2 inhibitors’ treatment in lupus nephritis (LN).2 We completely understand your concerns and share the same perplexity regarding the reduced total IgG and dsDNA levels by empagliflozin in animal experiments, as you do. Hypogammaglobulinaemia has not been reported in any trials of SGLT2 inhibitors, and the immunosuppressive effects cannot be explained so far. These questions are of utmost importance and warrant further experiments for clarification. Recently, immunological properties have been implicated for SGLT2 inhibitors and were summarised by Bendotti et al.3 Canagliflozin, not dapagliflozin, can suppress T-cell function, making it a promising option for T-cell-mediated autoimmune diseases.4 5 This is due to the off-target effects of canagliflozin, and dapagliflozin or empagliflozin have no known off-target effects. Empagliflozin, the one...
15. mai 2024
In my remarks offered to you at the beginning of this year, I addressed the many anniversaries that would be 2024 highlights.1 But I deliberately omitted one significant anniversary, preferring to wait to this moment to reflect that this year EULAR is organising the 25th EULAR Annual Congress. This is not only a reason to celebrate a quarter century of a scientific and educational event characterised by ever increasing numbers of attendees, but also a timely reminder that the very first annual meeting held in Nice in 2000 took place at a time when the first biological agents for an immune-mediated disease, in particular rheumatoid arthritis (RA), had just been approved in Europe. These medicines changed the course of this and thereafter many other chronic immune-mediated inflammatory diseases (IMIDs) in a dramatic way.2 3 Thus, the history of the EULAR congresses parallels the...
Annals of the Rheumatic Diseases
Hva synes du om denne siden?
Gi oss tilbakemelding